MedTrace Logo

Efficacy and Safety of Candesartan Associated With Chlorthalidone in Essential Arterial Hypertension Control

NCT02521233 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2017-01-19

No results posted yet for this study

Summary

The purpose of this study is to evaluate the non-inferiority clinical efficacy of two different drug associations in the essential hypertension control.

Conditions

  • Essential Arterial Hypertension

Interventions

DRUG

Candesartan + Chlorthalidone (8mg+12,5mg)

DRUG

Candesartan + Chlorthalidone (8 mg + 25 mg)

DRUG

losartan+hydrochlorothiazide

Sponsors & Collaborators

  • EMS

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-30
Primary Completion
2017-05-31
Completion
2017-08-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02521233 on ClinicalTrials.gov